As Senior Vice President of Dry Eye at Ora, George Ousler oversees all dry eye clinical programs, lending his therapeutic knowledge and expertise to see each development project through to completion. He develops clinical models and regulatory pathways for the evaluation of dry eye therapies and has studied many of the agents under investigation. The Dry Eye Department includes nearly 60 team members who work with global clients in the U.S., Europe and Asia, including Japan, China and South Korea. George has more than 20 years of pioneering pharmaceutical development in the area of dry eye. He has authored more than 250 publications on the topic and has been invited to present his research at numerous national and international symposia. He also holds a number of patents on techniques, formulations and methods in the area of dry eye and related conditions. During his time at Ora, George has been pivotal in the development and success of U.S. Food and Drug Administration-approved products to treat dry eye, including Xiidra® and TrueTear™ Intranasal Tear Neurostimulator. He often is called on to consult on worldwide drug development and registration, and frequently interacts with several regulatory agencies, including the U.S. FDA, the European Medicines Agency, the China Food and Drug Administration and the Pharmaceuticals and Medical Device Agency (Japan). Earlier positions in Ora’s Dry Eye Department include Director, Senior Clinical Manager, Clinical Manager and Clinical Research Associate. George serves on several noted dry eye research committees and Scientific Advisory Boards. He is a member of several ophthalmic professional organizations, including the Association for Research in Vision and Ophthalmology, the Sjögren’s Society and the Tear Film & Ocular Surface Society and is a reviewer for numerous scientific journals.